Objective To investigate baseline use of biologic or targeted synthetic (b/ts) disease-
modifying antirheumatic drugs (DMARDs) and COVID-19 outcomes in rheumatoid arthritis …

COVID-19 emerged from China in December 2019 and during 2020 spread to every
continent including Antarctica. The coronavirus, SARS-CoV-2, has been identified as the …

Many nations are pursuing the rollout of SARS-CoV-2 vaccines as an exit strategy from
unprecedented COVID-19-related restrictions. However, the success of this strategy relies …

The SARS-CoV-2 Omicron (B. 1.1529) variant was designated as a variant of concern (VOC)
by the World Health Organization (WHO) on November 26, 2021. Within two months, it had …

The COVID-19 pandemic has profound adverse effects on the population on dialysis.
Patients requiring dialysis are at an increased risk of SARS-CoV-2 infection and mortality …

Background Reinfection with the severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2) has been documented, raising public health concerns. SARS-CoV-2 reinfections …

There is intense interest in antibody immunity to coronaviruses. However, it is unknown if
coronaviruses evolve to escape such immunity, and if so, how rapidly. Here we address this …

Adaptive immune responses play critical roles in viral clearance and protection against re‐
infection, and SARS‐CoV‐2 is no exception. What is exceptional is the rapid …

While the standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two
doses administered 3 weeks apart, some public health authorities are spacing these doses …

Vaccine-mediated immunity often relies on the generation of protective antibodies and
memory B cells, which commonly stem from germinal center (GC) reactions. An in-depth …